Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427252 | 0.81 | NOS1 (0.46) | ROCK2SCDELANEBCHEGPR119 | |
| SCHEMBL17648499 | 0.81 | ROCK2 (0.43) | ROCK2SCDNR1H2ELANEBCHE | |
| SCHEMBL21121081 | 0.80 | ROCK2 (0.41) | ROCK2SCDGABRG2GABRB3GABRA5 | |
| SCHEMBL2549524 | 0.79 | ELANE (0.47) | ROCK2SCDNR1H2ELANEBCHE | |
| SCHEMBL18083986 | 0.79 | ROCK2 (0.43) | ROCK2SCDNR1H2ELANEBCHE | |
| SCHEMBL11901149 | 0.79 | ROCK2 (0.43) | ROCK2SCDGABRG2GABRB3GABRA5 | |
| SCHEMBL671541 | 0.79 | ROCK2 (0.45) | ROCK2SCDNR1H2ELANEBCHE | |
| SCHEMBL22353102 | 0.78 | ROCK2 (0.42) | ROCK2SCDELANEGPR119PLAU | |
| SCHEMBL27787108 | 0.78 | ROCK2 (0.42) | ROCK2SCDELANEGPR119KDM4E | |
| SCHEMBL13267264 | 0.78 | SCD (0.44) | ROCK2SCDNR1H2ELANEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139546-B2 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2015-09-22 | — | — | US | claimed |
| US-20110207748-A1 | Tri-Aryl/Heteroaromatic Cannabinoids and Use Thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2011-08-25 | — | — | US | claimed |
| US-7888365-B2 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2011-02-15 | — | — | US | claimed |
| EP-2131655-A2 | TRI-ARYL/HETEROAROMATIC CANNABINOIDS AND USE THEREOF | The University of Tennessee Research Foundation (US) | 2009-12-16 | — | — | EP | claimed |
| US-20080234293-A1 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2008-09-25 | — | — | US | claimed |
| WO-2008109027-A2 | TRI-ARYL/HETEROAROAROMATIC CANNABINOIDS AND USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE (US) | 2008-09-12 | — | — | WO | claimed |
| US-20260137706-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4724440-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | Interline Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250171439-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250051313-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-02-13 | — | — | US | disclosed |
| WO-2024254539-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20240368078-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2024-11-07 | — | — | US | disclosed |
| WO-2024217515-A1 | HETEROCYCLIC RING-SUBSTITUTED AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海复宏汉霖生物技术股份有限公司 | 2024-10-24 | — | — | WO | disclosed |
| WO-2008154642-A2 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080234293-A1 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2008-09-25 | — | — | US | disclosed |
| WO-2008109027-A2 | TRI-ARYL/HETEROAROAROMATIC CANNABINOIDS AND USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE (US) | 2008-09-12 | — | — | WO | disclosed |
| US-6548512-B1 | Pyrazole derivatives such as 1-(3-amidinophenyl)-3-methyl-2-((5-(2'-aminosulfonylphenyl-1-yl)pyrimidin-2 -yl)aminocarbonyl)pyrazole; treating thromboembolic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-6020357-A | CARDIOVASCULAR DISORDERS; ANTCOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0946508-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028269-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137706-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | NR3C1, CCR1, CXCR2 | ROCK2 2466/4885SCD 1301/4885GABRG2 2703/4885 |
| US-20080234293-A1 | Tri-aryl/heteroaromatic cannabinoids and use thereof | CNR1, CNR2, OPRM1 | ROCK2 4047/4885SCD 1515/4885GABRG2 142/4885 |
| US-20250051313-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | PDK4, PDK2, PDK3 | ROCK2 3464/4885SCD 1549/4885GABRG2 3628/4885 |
| US-20110207748-A1 | Tri-Aryl/Heteroaromatic Cannabinoids and Use Thereof | CNR1, CNR2, OPRM1 | ROCK2 4047/4885SCD 1515/4885GABRG2 142/4885 |
| US-20240368078-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNH2, KCNH3 | ROCK2 4497/4885SCD 3613/4885GABRG2 279/4885 |
| US-20250171439-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | GRIN2B, HTR2B, HTR1A | ROCK2 253/4885SCD 1617/4885GABRG2 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.